IRCT201407155368N2CompletedPhase 1
Studying safety and efficacy of Bumetanide on relief of pharmacological treatment-resistant pain in spinal cord injury patients refered to pain clinic of Brain And Spinal Cord Injury Research Center, Emam Khomeini Hospital, Tehran, during years 1392 through 1393
Brain and Spinal Cord Injury Research Center0 sites15 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Enrollment
- 15
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- no limit to no limit (—)
- Sex
- All
Inclusion Criteria
- •Inclusion Criteria: All the patients with spinal cord injury and refractory at- or below-level pain due to the injury who signed the informed consent.
Exclusion Criteria
- •History of renal failure; Creatinine more than 1.5 mg/dl or its increase at least 0.5 mg/dl during study; Cardiovascular diseases including heart failure, conductive disorders and MI; Hypokalemia during study; During Breast feeding; History of hypersensitivity to sulfonamides, sulfunilurea, carbonic anhydrase inhibitors and thiazides; Using cross-reacting medications like Heart Glycosides, Cisplatin, Glucocorticoids, Cyclosporine, ACE Inhibitors, Aminoglycosides, Beta2 Agonists, Allopurinol, Dofetilide, Probenecid, Risperidone, Sodium Phosphates and Topiramate.
Investigators
Similar Trials
Active, not recruiting
Phase 1
Efficacy and safety of bumetanide oral liquid formulation in children and adolescents aged from 7 to less than 18 years old with Autism Spectrum Disorder.Autism Spectrum Disorder (ASD)MedDRA version: 20.0 Level: PT Classification code 10063844 Term: Autism spectrum disorder System Organ Class: 10037175 - Psychiatric disordersEUCTR2017-004419-38-IEInstitut de Recherches Internationales Servier200
Active, not recruiting
Phase 1
Efficacy and safety of bumetanide oral liquid formulation in children aged from 2 to less than 7 years old with Autism Spectrum Disorder.Autism Spectrum Disorder (ASD)MedDRA version: 20.0Level: PTClassification code 10063844Term: Autism spectrum disorderSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2017-004420-30-FRInstitut de Recherches Internationales Servier200
Active, not recruiting
Phase 1
Efficacy and safety of bumetanide oral liquid formulation in children and adolescents aged from 7 to less than 18 years old with Autism Spectrum Disorder.Autism Spectrum Disorder (ASD)MedDRA version: 20.0Level: PTClassification code 10063844Term: Autism spectrum disorderSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2017-004419-38-ESInstitut de Recherches Internationales Servier211
Active, not recruiting
Phase 1
Efficacy and safety of bumetanide oral liquid formulation in children aged from 2 to less than 7 years old with Autism Spectrum Disorder.Autism Spectrum Disorder (ASD)MedDRA version: 21.1Level: PTClassification code 10063844Term: Autism spectrum disorderSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2017-004420-30-CZInstitut de Recherches Internationales Servier200
Active, not recruiting
Phase 1
Efficacy and safety of bumetanide oral liquid formulation in children and adolescents aged from 7 to less than 18 years old with Autism Spectrum Disorder.Autism Spectrum Disorder (ASD)MedDRA version: 21.1Level: PTClassification code 10063844Term: Autism spectrum disorderSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2017-004419-38-CZInstitut de Recherches Internationales Servier211